Acetyl-APEX1 (K7) Antibody

What is APEX1 and why is its acetylation at K7 significant?

APEX1 (apurinic/apyrimidinic endonuclease 1, also known as APE1/Ref-1) is a multifunctional protein that plays critical roles in:

• Base excision repair (BER) pathway for repairing oxidized and alkylated bases

• Redox regulation of transcription factors such as AP-1, HIF-1α, and p53

• Direct transcriptional regulation of genes like PTH, renin, and PTEN

Acetylation at Lysine 7 (K7) is a significant post-translational modification of APEX1 that modulates its transcriptional regulatory functions. Research indicates that:

• K7 acetylation enhances APEX1's binding to the negative calcium response element (nCaRE-B)

• This modification influences APEX1's protein-protein interactions with transcriptional co-factors such as YB-1, HIF-1α, and p300

• K7 is conserved in most mammalian APEX1 including human, mouse, and bovine, though interestingly it is not conserved in rat and Chinese hamster

How can I validate that my Acetyl-APEX1 (K7) antibody is specific?

To validate Acetyl-APEX1 (K7) antibody specificity, employ these methodological approaches:

• Comparative Western blotting:

  • Test antibody recognition of recombinant WT APEX1 versus K7R mutant proteins

  • Compare endogenous APEX1 detection in samples treated with or without HDAC inhibitors (to increase acetylation levels)

• Immunoprecipitation validation:

  • Perform IP with anti-APEX1 antibody followed by Western blot with anti-Acetyl-K7 antibody

  • Reverse IP with anti-Acetyl-K7 antibody followed by detection with total APEX1 antibody

• Peptide competition assay:

  • Pre-incubate antibody with acetylated and non-acetylated APEX1 peptides containing K7

  • Reduction in signal only with acetylated peptide confirms specificity

• Mass spectrometry validation:

  • Immunoprecipitate APEX1 and perform MS analysis to confirm K7 acetylation

  • Compare MS results with antibody-based detection methods

As demonstrated in research, affinity-purified AcAPE1-specific antibodies can be highly specific when properly validated, not cross-reacting with at least 25-fold excess unmodified APE1 .

What are the recommended applications for Acetyl-APEX1 (K7) antibodies?

Based on current research protocols, Acetyl-APEX1 (K7) antibodies can be effectively used in:

When using these antibodies, researchers should be aware that:

• Different subcellular fractionation techniques may affect detection efficiency

• Acetylation levels can vary significantly depending on cell type and experimental conditions

• Buffer compositions may influence antibody recognition of the acetylated epitope

How do cellular stressors affect APEX1 acetylation at K7?

APEX1 acetylation at K7 is dynamically regulated by cellular stress conditions:

• Oxidative stress:

  • H₂O₂ treatment increases APEX1 acetylation

  • Promotes interaction between APEX1 and p300 acetyltransferase

• Genotoxic stress:

  • DNA-damaging agents induce APEX1 acetylation

  • Associated with increased nuclear translocation

  • Promotes APEX1 recruitment to damaged DNA sites

• Inflammatory stimuli:

  • TNF-α exposure enhances APEX1 acetylation

  • Oscillatory shear stress (OS) promotes APEX1 acetylation in endothelial cells

• Hypoxia:

  • Enhances APEX1 acetylation and association with HIF-1α

  • Critical for formation of hypoxia-inducible transcriptional complex on VEGF promoter

Experimentally, HDAC inhibitors can be used to increase APEX1 acetylation, mimicking stress conditions and enhancing nuclear localization .

How does acetylation of APEX1 at K7 impact its subcellular localization and function?

K7 acetylation critically regulates APEX1's subcellular distribution and functional activities:

Subcellular localization changes:

• Acetylated APEX1 shows predominant nuclear localization compared to the unmodified form

• K7 acetylation affects nucleolar localization patterns in a cell cycle-dependent manner

• APEX1 can be found in multiple compartments including nucleus, nucleolus, nucleus speckle, endoplasmic reticulum, and cytoplasm

Functional impacts:

• Transcriptional regulation:

  • Enhanced binding to nCaRE sequences in gene promoters

  • Increased interaction with transcriptional machinery components

  • Critical for Egr-1-mediated activation of PTEN expression

• Protein-protein interactions:

  • K7 acetylation promotes APEX1 association with:

    • HIF-1α, STAT3, and CBP/p300 in hypoxia-induced transcriptional complexes

    • YB-1, leading to activation of multidrug resistance (MDR1) gene expression

    • p300, HDAC1, and other transcriptional regulators

• Biomolecular condensate formation:

  • Recent evidence suggests acetylation may influence APEX1's ability to form biomolecular condensates in nucleoli

  • These condensates may recruit ATR and its activators TopBP1 and ETAA1

Research methodologies to study these impacts include subcellular fractionation, co-immunoprecipitation experiments, chromatin immunoprecipitation, and advanced imaging techniques.

What is the relationship between APEX1 acetylation and the DNA damage response pathway?

APEX1 acetylation plays sophisticated roles in DNA damage response (DDR) pathways:

ATR-Chk1 DDR pathway:

• Recent studies reveal that APE1 is critical for ATR-Chk1 DDR activation under stress conditions

• While APE1's nuclease activity is important for processing damaged DNA in this pathway, the N-terminal region (containing K7) has been implicated in promoting biomolecular condensates that activate ATR signaling independent of nuclease activity

• These APE1-mediated condensates recruit ATR and its activators TopBP1 and ETAA1, facilitating checkpoint activation

Experimental evidence of pathway connection:

• APE1 overexpression activates ATR-Chk1 DDR under unperturbed conditions

• This activation is independent of APE1 nuclease and redox functions

• The extreme N-terminal 33 amino acids (containing K7) are required for biomolecular condensate assembly and DNA/RNA-independent activation of ATR DDR

Methodological approaches to study this relationship:

• Utilize site-specific acetylation mutants (K7R) to determine the specific contribution of K7 acetylation

• Employ APE1 inhibitors (AR03, APE1i III, E3330) alongside acetylation-specific antibodies to distinguish between functions

• Analyze the effects of HDAC inhibitors on APE1 acetylation status and DDR pathway activation

• Perform FACS analysis to determine cell cycle effects after modulating APEX1 acetylation

How can I distinguish between the effects of acetylation at K7 versus other lysine residues in APEX1?

Distinguishing between acetylation at different lysine residues requires sophisticated experimental approaches:

Site-specific mutant analysis:

• Generate single-site mutants (K6R, K7R, K27R, K31R, K32R, K35R)

• Create combinatorial mutants (K6R/K7R or K6L/K7L) to assess potential cooperative effects

• Compare functional outcomes across mutants to map residue-specific contributions

Mass spectrometry-based approaches:

• Employ targeted MS/MS to identify and quantify site-specific acetylation

• Use SILAC or TMT labeling to compare acetylation patterns across conditions

• Apply parallel reaction monitoring for accurate quantification of each acetylation site

Site-specific antibodies:

• Use antibodies targeting different acetylated lysines in APEX1

• Compare localization patterns, protein interactions, and functional outcomes

• Employ peptide competition assays with differentially acetylated peptides

Research findings:

• K6 and K7 are both acetylated by p300, but mass spectrometry has not detected diacetylated APE1, suggesting steric hindrance - either K6 or K7 but not both can be acetylated in the same molecule

• K7 is evolutionarily conserved in most mammals but not in rat and Chinese hamster, suggesting specific biological functions

• APEX1 can be posttranslationally modified via acetylation on multiple lysine residues (K6, K7, K27, K31, K32, and K35), each potentially conferring distinct functions

What mechanisms regulate APEX1 acetylation and deacetylation?

APEX1 acetylation is governed by a dynamic equilibrium between acetylation and deacetylation processes:

Acetyltransferases:

• p300/CBP: Directly acetylates APEX1 at K6 and K7 both in vivo and in vitro

• Evidence: Immunoprecipitation experiments demonstrate enhanced p300-APEX1 interaction under stress conditions (oscillatory shear stress, oxidative stress)

• Regulation: Stress conditions such as oxidative stress (H₂O₂) strongly stimulate p300 association with APEX1

Deacetylases:

• HDAC1: Evidence suggests interaction with APEX1 to regulate its acetylation status

• SIRT1: Colocalizes with APEX1 in the nucleus and may regulate its acetylation status

• Functional validation: Treatment with HDAC inhibitors increases APEX1 acetylation and induces PTEN expression

Regulatory mechanisms:

• Shear stress response:

  • Oscillatory shear stress enhances APEX1 acetylation compared to pulsatile shear

  • This promotes nuclear translocation of APEX1 and inflammatory gene activation

• Redox signaling:

  • Oxidative stress conditions promote APEX1 acetylation

  • H₂O₂ treatment induces p300-APEX1 interaction and subsequent acetylation

• Inflammatory stimuli:

  • TNF-α induces APEX1 acetylation, promoting its nuclear translocation

Experimental approaches to study regulation:

• HDAC inhibitors can be used as tools to increase APEX1 acetylation

• CETSA (Cellular Thermal Shift Assay) can measure drug-target engagement for compounds affecting APEX1 acetylation

• Isothermal dose-response experiments can quantify effects of regulators on APEX1 stability and modification

How can Acetyl-APEX1 (K7) antibodies be used to study cancer chemoresistance mechanisms?

Acetyl-APEX1 (K7) antibodies provide valuable tools for investigating cancer chemoresistance:

Molecular basis for investigation:

• APEX1 acetylation enhances its interaction with Y-box-binding protein 1 (YB-1), activating multidrug resistance gene (MDR1) expression

• APE1 is overexpressed in many tumor cell lines and can be serum-secreted in different cancers

• Acetylated APEX1 regulates RNA metabolism including processing damaged RNA in chemoresistant phenotypes

Methodological approaches:

• Treatment response monitoring:

  • Measure Acetyl-APEX1 (K7) levels before and after chemotherapy exposure

  • Correlate acetylation status with drug resistance profiles

  • Compare acetylation patterns between sensitive and resistant cell populations

• Mechanistic investigations:

  • Use ChIP assays with Acetyl-APEX1 (K7) antibodies to map genomic binding sites in resistant vs. sensitive cells

  • Perform RIP (RNA immunoprecipitation) to identify RNA targets of acetylated APEX1

  • Study interactions between acetylated APEX1 and other chemoresistance mediators (YB-1, STAT3)

• Therapeutic targeting assessment:

  • Monitor APEX1 acetylation status when testing APEX1 inhibitors

  • Combine HDAC inhibitors with conventional chemotherapy to modulate APEX1 acetylation

  • Develop strategies targeting acetylated APEX1 specifically

Research findings and applications:

• APE1 forms biomolecular condensates in nucleoli in cancer cells but not in non-malignant cells, with potential implications for DNA damage response

• APE1 overexpression-induced activation of ATR-Chk1 DDR is independent of APE1 nuclease activities and redox function, suggesting acetylation-dependent mechanisms may be involved

• APE1 has emerged as a promising therapeutic target in cancer, and understanding its acetylation state may enhance targeting strategies

What are common technical issues when using Acetyl-APEX1 (K7) antibodies and how can they be resolved?

Researchers often encounter these technical challenges when working with Acetyl-APEX1 (K7) antibodies:

Issue 1: High background signal

• Causes: Non-specific binding, excessive antibody concentration, insufficient blocking

• Solutions:

  • Optimize blocking conditions (5% BSA often performs better than milk for phospho/acetyl antibodies)

  • Titrate antibody concentration (start at 1:1000 and adjust as needed)

  • Include competitive peptides to reduce non-specific binding

  • Use highly purified antibody preparations

Issue 2: Weak or no signal detection

• Causes: Low acetylation levels, epitope masking, protein degradation

• Solutions:

  • Pre-treat samples with HDAC inhibitors to increase acetylation levels

  • Optimize extraction buffers to include deacetylase inhibitors

  • Use fresh samples and avoid freeze-thaw cycles

  • Try alternative detection methods (chemiluminescence vs. fluorescence)

Issue 3: Inconsistent results across experiments

• Causes: Variable acetylation levels, different cellular states, technical variability

• Solutions:

  • Standardize cell culture conditions and treatments

  • Include positive controls (HDAC inhibitor-treated samples)

  • Normalize to total APEX1 levels in parallel samples

  • Maintain consistent experimental conditions (buffer compositions, incubation times)

Issue 4: Difficulties in subcellular localization studies

• Causes: Fixation affecting epitope accessibility, extraction methods disrupting localization

• Solutions:

  • Test multiple fixation methods (paraformaldehyde vs. methanol)

  • Optimize permeabilization conditions

  • Use subcellular fractionation as complementary approach

  • Compare results with total APEX1 localization patterns

How can I correlate APEX1 K7 acetylation with functional outcomes in my experimental system?

To establish meaningful correlations between K7 acetylation and functional outcomes:

Experimental design approaches:

• Temporal analyses:

  • Track K7 acetylation kinetics following stimulus application

  • Correlate acetylation timing with downstream functional changes

  • Use time-course analyses to establish cause-effect relationships

• Spatial correlation:

  • Use immunofluorescence to correlate subcellular localization of acetylated APEX1 with function

  • Analyze nuclear vs. cytoplasmic distribution under different conditions

  • Examine co-localization with functional partners (transcription factors, DNA repair machinery)

• Genetic manipulation strategies:

  • Compare wild-type vs. K7R mutant (acetylation-deficient) APEX1

  • Use CRISPR-Cas9 to introduce K7Q mutations (acetylation mimetic)

  • Employ inducible expression systems to control acetylation timing

• Pharmacological interventions:

  • Modulate acetylation with HDAC inhibitors and monitor functional changes

  • Use p300 inhibitors to reduce acetylation

  • Apply APEX1 inhibitors like E3330 or vitexin to assess functional consequences

Functional readouts:

• Transcriptional regulation: ChIP-seq, RNA-seq, reporter assays

• DNA repair capacity: Comet assays, γH2AX foci formation

• Protein interactions: Co-IP, proximity ligation assays

• Cell phenotypes: Viability, apoptosis, cell cycle distribution, chemosensitivity

Research findings indicate that acetylation of APEX1 enhances binding to nCaRE-B and influences transcriptional outcomes including Egr-1-mediated activation of PTEN expression , providing a model for correlation studies.

How does APEX1 K7 acetylation influence biomolecular condensate formation and function?

Recent discoveries have revealed intriguing connections between APEX1 acetylation and biomolecular condensate formation:

Current understanding:

• APEX1 can assemble distinct biomolecular condensates in a DNA/RNA-independent manner

• These condensates recruit ATR and its direct activators TopBP1 and ETAA1

• APEX1 forms biomolecular condensates specifically in nucleoli in cancer cells but not in non-malignant cells

Methodological approaches to study this phenomenon:

• Advanced imaging techniques:

  • Fluorescence recovery after photobleaching (FRAP) to assess condensate dynamics

  • Stimulated emission depletion (STED) microscopy for super-resolution imaging

  • Live-cell imaging with fluorescently tagged proteins to track condensate formation

• Biochemical analyses:

  • In vitro reconstitution of phase separation with purified components

  • Turbidity assays to quantify phase separation properties

  • Differential centrifugation to isolate condensates

• Mutational studies:

  • Compare wild-type vs. K7R mutant APEX1 for condensate formation

  • Analyze the extreme N-terminal 33 amino acids (containing K7) for their role in condensate assembly

  • Test W119R mutant, which is deficient in nucleolar condensation and liquid-liquid phase separation

Research implications:

• APEX1 condensates may function as reaction hubs for DNA damage response pathway activation

• Cancer cells might utilize acetylated APEX1-mediated condensates for survival advantage

• Targeting these condensates could represent a novel therapeutic approach

What is the relevance of APEX1 K7 acetylation in cardiovascular disease and therapeutic targeting?

Emerging research highlights APEX1 K7 acetylation as a critical factor in cardiovascular pathophysiology:

Vascular endothelial inflammation:

• Oscillatory shear stress (OS) promotes APEX1 acetylation and nuclear translocation in endothelial cells

• Acetylated APEX1 acts as a shear stress-sensitive molecule that orchestrates proinflammatory responses

• Depletion of endothelial Apex1 in mice ameliorated atherogenesis

Mechanisms in cardiovascular disease:

• Flow-mediated responses:

  • OS induces APEX1 acetylation via promoting its interaction with acetyltransferase p300

  • Acetylated APEX1 translocates to the nucleus and activates proinflammatory genes

  • This process is inhibited by natural compounds like vitexin

• NF-κB pathway regulation:

  • Acetylated APEX1 promotes nuclear translocation of p50 and p65 NF-κB subunits

  • OS-induced activation of APEX1 leads to enhanced NF-κB-mediated inflammatory gene expression

  • This mechanism connects hemodynamic forces to inflammatory responses in atheroprone regions

Therapeutic targeting approaches:

• Vitexin, a natural flavonoid, directly binds to APEX1 (KD = 2.344 × 10⁻⁵ mol/L)

• This interaction inhibits OS-induced APEX1-p300 binding, acetylation, and nuclear translocation

• Treatment with vitexin suppressed flow-induced endothelial inflammation and ameliorated atherosclerosis in hyperlipidemic mice

Experimental methods for investigation:

• CETSA (Cellular Thermal Shift Assay) to measure drug-target engagement

• SPR (Surface Plasmon Resonance) to quantify binding kinetics

• Isothermal dose-response experiments to assess protein stabilization by compounds

How can single-cell analysis be applied to study APEX1 K7 acetylation heterogeneity in complex tissues?

Single-cell technologies offer powerful approaches to uncover APEX1 acetylation heterogeneity:

Methodological approaches:

• Single-cell immunofluorescence:

  • Multiplex staining for Acetyl-APEX1 (K7) and cell type markers

  • Quantitative image analysis to measure acetylation levels across cell populations

  • Correlation with functional cellular states (proliferation, stress, differentiation)

• Mass cytometry (CyTOF):

  • Development of metal-conjugated Acetyl-APEX1 (K7) antibodies

  • Simultaneous detection of multiple cellular markers and acetylation status

  • High-dimensional data analysis to identify cell clusters with distinct acetylation patterns

• Single-cell proteomics:

  • Adaptation of nano-proteomics techniques for acetylation detection

  • Analysis of correlation between APEX1 acetylation and other protein modifications

  • Integration with single-cell transcriptomics data

• Spatial transcriptomics/proteomics:

  • Mapping acetylation patterns in tissue contexts while preserving spatial information

  • Correlation with local tissue microenvironments and disease features

  • Detection of acetylation gradients associated with tissue structures

Research applications:

• Analysis of tumor heterogeneity in acetylation patterns

• Identification of rare cell populations with altered APEX1 function

• Correlation of acetylation status with disease progression markers

• Mapping acetylation patterns in atherosclerotic plaques or other complex disease tissues

Technical considerations:

• Need for highly specific antibodies with low background for single-cell applications

• Optimization of fixation and permeabilization protocols for acetylation epitope preservation

• Development of quantitative standards for acetylation level normalization

• Integration of computational approaches for multi-parameter data analysis